All News

RheumNow Podcast square

Bad Actor Cofactor (10.17.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports, discusses pediatric reports, pregnancy data, diet and nutrition and more.

Read Article
lupus_0.jpg

Telitacicept Effective in Systemic Lupus Erythematosus

Jack Cush, MD

The NEJM has published a report from van Vollenhoven et al showing a new dual B cell inhibitor, telitacicept, to be effective when given to active systemic lupus erythematosus (SLE) patients; but this comes with a few safety concerns.

Read Article
pregnant, pregnancy, mother, fertility

Pregnancy Management in Inflammatory Bowel Disease: A Global Consensus

Jack Cush, MD

Consensus guidance on the management of pregnancy in patients with inflammatory bowel disease (IBD) was simultaneously published in six international journals, including The American Journal of Gastroenterology.

Read Article
RheumNow Podcast square

Eating Crow (10.10.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, FDA approvals, and journal articles. In this episode: HMGCR Abs, FDA approvals and Cush eats crow.

Read Article
RA Hands Difficult deformity

Not all difficult-to-treat RA will have rapid radiographic progression

Jack Cush, MD

A study of radiographic outcomes in difficult-to-treat rheumatoid arthritis (D2T RA) and poly-refractory RA (pr-RA) show a subset in whom damage is rapid and in need of more aggressive therapy.

Read Article
RheumNow Podcast square

How Does Your Garden Grow (9.26.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Pool therapy, Fibrosis, NSIE's and what's best for knee OA. 

Read Article
RheumNow Podcast square

Big Fat FDA Pink Slip (9.19.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com. Today we cover GLP-1 agonists, acupuncture, what JAKs won’t do & an FDA Pink Slip. 

Read Article
GLP-1.pink

GLP-1 Drugs Reduce Rheumatoid Arthritis Symptoms

MedPage Today

Patients with rheumatoid arthritis (RA) who used GLP-1 receptor agonists had less disease activity and improved cardiovascular biomarkers, a small retrospective study indicated.

Read Article
lung.pulmonary.fibrosis.IPF

What you need to know about scleroderma-related lung fibrosis

Dinesh Khanna, MD, MSc

What do you need to know about scleroderma-related lung fibrosis as a practicing rheumatologist? Here are takeaways from these guidelines and my practice.

Read Article
FDA has approved nerandomilast (PDE4b inhibitor) for treatment of adults with idiopathic pulmonary fibrosis (IPF). Approval is based on 2 RCTs, FIBRONEER-IPF & FIBRONEER-ILD, that show slowing of lung function decline IP & progressive pulmonary fibrosis (PPF) pts. https://t.co/pIQwyLUBoj
Dr. John Cush RheumNow ( View Tweet)
FDA Approves Deuruxolitinib for use in adult patients with moderate to severe Alopecia Areata https://t.co/D6KXtDjfHL https://t.co/2WSIBWNexX

Links:

Dr. John Cush RheumNow ( View Tweet)
Post hoc analyses of (FUTURE 5) 541 active PsA pts Rx w/ secukinumab shows NO radiographic progression through 2 years of SEC was assoc with achieving LDA at Week 104. https://t.co/IyCsJOm9PS https://t.co/PgDKanxaNU

Links:

Dr. John Cush RheumNow ( View Tweet)
CAR-T Product Shows Early Promise in Lupus Five patients with systemic lupus erythematosus (SLE) in China have been treated with a potentially groundbreaking form of chimeric antigen receptor (CAR) T-cell therapy, researchers reported, with encouraging results after 3 months. https://t.co/eg37PZK6kn
Dr. John Cush RheumNow ( View Tweet)
Canakinumab in VEXAS - 47 males Rx w/ anakinra (44), canakinumab (9), or both(6). Response @1 mos: ANAK 34% vs CANK 100%; 22% vs 78% @ 3 mos. Drug survival was 54 mos CANK 300/m; 7 mo CANK 150/m; 1 mo ANAK. More ISR (47% v 0) & infx w/ ANAK https://t.co/Y3iSfajTal https://t.co/qTNamGDwVI

Links:

Dr. John Cush RheumNow ( View Tweet)
Big Fat FDA Pink Slip (9.19.2025) Dr. Jack Cush reviews the news and journal reports from this week on RheumNow. Today we cover GLP-1 agonists, acupuncture, what JAKs won’t do & an FDA Pink Slip. https://t.co/Za39hxI8Qf https://t.co/yN4K9tOuTt

Links:

Dr. John Cush RheumNow ( View Tweet)
Sucutaneous anifrolumab? Phase III TULIP-SC trial in SLE patients showed SC anifrolumab (Saphnelo) significantly reducted lupus disease activity compared to placebo. https://t.co/vvI2av2vAJ https://t.co/0V1wsmFk0N

Links:

Dr. John Cush RheumNow ( View Tweet)
Guselkumab (Tremfya) 1st IL-23 inhibitor to be FDA approved for subcutaneous induction in adults with ulcerative colitis https://t.co/KaZVzyomeY

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of 43 PsA pts starting bDMARD shows Calprotectin was elevated in PsA, decreased w/ biologics, but had no signif correlation w/ US synovitis. Baseline calprotectin, S100A12, IL-6, IL-17A, IL-23, CXCL10 were high. Calprotectin, S100A12, IL-6 decreased w/ Rx (p < 0.05).

Dr. John Cush RheumNow ( View Tweet)

What are the Pros and Cons of autologous CAR T cell therapy? Summary slide from Georg Schett who also mentioned the exciting in vivo CAR approach using nanoparticules in myeloma, something to stay tuned for @RheumNow #APLAR25 https://t.co/kWjrx6N9Dv

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Different B cells depletion strategies in SARDs highlighted by Georg Schett From low and short lived depletion achieved w/ drugs to sustained deep tissular depletion with CAR T cells leading to potential immune reset @RheumNow #APLAR25 https://t.co/t35lrzEomF

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×